Drugs / Recombinant human interferon α1β
Recombinant human interferon α1β
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04293887 | Mar → May 2020 | COVID-19, interferon antiviral depressor | Tongji Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant human interferon α1β | “Recombinant human interferon α1β” NCT04293887 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant human interferon α1β” NCT04293887 ↗ |
| Route | Inhaled | “nebulization inhalation” NCT04293887 ↗ |